Interestingly, the post hoc analyses of the pivotal trials, DELIVER and DAPA-HF trials, confirmed that the positive effects of SGLT2 inhibitors on the CV adverse outcomes were consistent across the different levels of FI. Here, SLC5A2 is linked to hydrops fetalis.